View Cart  

Devicemakers Question Value of CMS, FDA Parallel Review

A A
Despite claims by the FDA and Centers for Medicare & Medicaid Services (CMS) that parallel review could expedite marketing of new devices, industry fears the opposite could happen, depending on how the program is implemented.

To View This Article:

Login

Subscribe To Devices & Diagnostics Letter

Buy This Article Now

Add this article to your cart for $10.00